Fig. 4.

Stable EDD knockdown increases cisplatin sensitivity. (A) ES-2, (B) A2780ip2 and (C) OVCAR5 cells were retrovirally transduced with control or one of three EDD shRNAs and clones (ES-2 and A2780ip2) or populations (OVCAR5) were selected. Cell lysates were immunoblotted for EDD expression. Multiple clones from the same shRNA are designated as A or B. (D) ES-2 control shRNA or EDD shRNA cells were treated with cisplatin for 72h and cell viability measured by MTS assay. Percent survival was plotted against the log of the cisplatin concentration. The results are from three independent experiments performed in quadruplicate. (E) A2780ip2 and (F) OVCAR5 shRNA cells were treated with cisplatin for 24h and cell lysates from floating and adherent cells were immunoblotted for EDD and PARP cleavage. The numbers underneath the blot represent the relative intensity of cleaved PARP in each lane compared with the first lane of each blot.